CZ Biomed Corporation
A Biotechnology Company
Skip to content
  • Home
  • Products
  • Research
  • News
  • About Us
  • Contact Us

News

July 17, 2017 8:27 a.m. ET

Kocal Consulting Corporation Announces Collaboration with South Korea’s Largest Hospital to Develop New Cancer Treatment

November 30, 2016

Kocal Consulting Corporation Celebrates New Consulting Agreement with CZ Biomed Corp to Help Deliver Real Value to Bio-Pharm World

November 11, 2015

CZ BioMed Corp. Announces 2.5 Year Survival of Stage 4 Colon Cancer Patient.
Cancer Free After RVLYSIS

August 26, 2013

CZ BioMed Corp. Announces Successful Reduction of Prostate Cancer Tumors
More Than 50% Using PRO-RVLYSIS®

August 16, 2012

CZ BioMed Corp. Announces Licensing of Key U.S. Patent From The University of Texas Health Science Center at San Antonio Regarding the Use of Respiratory Syncytial Virus (RSV) for Anti-Cancer Oncolytic Treatments

January 25, 2012

Prostate Cancer Trials Underway Overseas PRO-RVLYSIS(R) CZ BioMed Corp.

September 22, 2011

Prostate Cancer Cure United States Patent Application – CZ BioMed Corp.

September 8, 2011

PROGRESS IN PANCREATIC CANCER CURE RESEARCH PANRVLYSIS®

Aug 23, 2011

CZ BioMed Corp. Names Internationally Renowned Dr. Ronald E. Wheeler, M.D. as Medical Director of its Scientific and Medical Advisory Boards

May 3, 2011

BREAST CANCER CURE INTERNATIONAL PATENT APPLICATION # PCT/US2011/000602 CZ BioMed Corp.

Oct 12, 2010 12:23 ET

Research for Cancer Cure — RVLYSIS® CZ BioMed Corp.

  • U.S. Patent

  • BIO 2017

  • National Cancer Conference

     
  • Latest News

    • Collaboration with South Korea’s Largest Hospital to Develop New Cancer Treatment July 17, 2017
  • RSS Cancer Research News

    • American Cancer Society Launches Return to Screening Initiative with Support from Genentech February 25, 2021
      Nationwide Effort Aims to Increase Breast, Cervical, Colorectal, and Lung Cancer Screening Rates
    • Don't Let the COVID-19 Pandemic Stall Your Colorectal Cancer Screening February 25, 2021
      American Cancer Society urges people to talk to their doctor about getting back to screening
    • One-Third of Cancer Survivors Worried About Treatment and Healthcare Disruptions During the COVID-19 Pandemic February 24, 2021
    • American Cancer Society Statement Regarding Senator Bob Dole's Lung Cancer Diagnosis February 19, 2021
    • American Cancer Society Announces New Diversity in Cancer Research Program - Made Permanent By a $5 Million Grant from the Elizabeth and Phill Gross Family February 9, 2021
      The fund will create a permanent umbrella to develop initiatives to support researchers of color and increase diversity in cancer research and patient care
  • Published on Oct 13, 2016  


    Robert Andtbacka, MD, CM of the Huntsman Cancer Institute, Salt Lake City, UT discusses the use of oncolytic viruses at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria.

  • Health Care Forum “War on Cancer” (March 30th 2017-Singapore)

     
  • Announcements

    • Collaboration with South Korea’s Largest Hospital to Develop New Cancer Treatment
    • Partnerships with Bio-pharmaceutical Leaders
    • Oncolytic Virus Reduces Prostate Cancer
  • Related Articles

    Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferondependent antiviral defense - Research Article (Biomed Central)

    Childhood virus RSV shows promise against adult cancer. - Science Daily

    CZ BioMed licenses children’s virus turned anti-cancer agent. - San Antonio Business Journal
CZ Biomed Corporation
Proudly powered by WordPress.